Clioquinol treatment in familiar early onset of Alzheimer's disease: A case report

Pharmacopsychiatry

Volumn 38, Issue 4, 2005, Pages 178-179

  Ibach, Bernd ^a   Haen, E ^a   Marienhagen, J ^a   Hajak, G ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; AMYLOID TAU PROTEIN; CHOLINESTERASE INHIBITOR; CLIOQUINOL; CYANOCOBALAMIN; DONEPEZILE; GLUCOSE; MEMANTINE; UNCLASSIFIED DRUG;

ADULT; ALZHEIMER DISEASE; ARTICLE; BRAIN LEVEL; BRAIN METABOLISM; CASE REPORT; CEREBROSPINAL FLUID LEVEL; CLINICAL EXAMINATION; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEADACHE; HUMAN; LONG TERM CARE; MALE; NAUSEA; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SCORING SYSTEM;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BRAIN; CHELATING AGENTS; CLIOQUINOL; COGNITION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; RISK ASSESSMENT; TAU PROTEINS;

EID: 23044445773     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-871241     Document Type: Article

References (9)

1. Bush AI. The metallobiology of Alzheimer's disease. TINS 2003; 26: 207-214
2. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001; 30: 665-676
3. Clifford Rose F, Gawel M. Clioquinol neurotoxicity: an overview. Acta Neurol Scan Suppl 1984; 100: 137-145
4. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 21;349(6311): 704-706
5. Nakae K, Yamamoto S, Shigematsu I, Kono R. Relation between subacute myelo-optic neuropathy (S.M.O.N.) and clioquinol: nationwide survey. Lancet 1973; 1(7796): 171
6. Regland B, Lehmann W, Abedini I, Blennow K, Jonsson M, Karlsson I et al. Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord 2001; 12: 408-414
7. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003; 60: 1685-1691
8. Tabira T. Clioquinol's return: Cautions from Japan. Science 2001; 292: 2251
9. Yassin MS, Ekblom J, Xilinas M, Gottfries CG, Oreland L. Changes in uptake of vitamin B12 and trace metals in brains of mice treated with clioquinol. J Neurol Sci 2000; 173: 40-44